The mutant selection window in rabbits infected with Staphylococcus aureus

Journal of Infectious Diseases

Volumn 194, Issue 11, 2006, Pages 1601-1608

  Cui, Junchang ^a   Liu, Youning ^a   Wang, Rui ^a   Tong, Weihang ^a   Drlica, Karl ^b   Zhao, Xilin ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; LEVOFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HYPOTHESIS; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; MUTANT SELECTION WINDOW; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; COLONY COUNT, MICROBIAL; DIFFUSION CHAMBERS, CULTURE; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; RABBITS; SELECTION (GENETICS); STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 33845214017     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/508752     Document Type: Article

References (36)

1. Seppala H, Klaukka T, Vuopio-Varkila J, Maotiala A, Helenius H, Lager K. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337:441-6.
2. Cizman M. The use and resistance to antibiotics in the community. Int J Antimicrob Agents 2003; 21:297-307.
3. Hecker M, Aron D, Patel N, Lehmann M, Donskey C. Unnecessary use of antimicrobials in hospitalized patients. Arch Intern Med 2003; 163:972-8.
4. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges, and responses. Nature Med 2004; 10:S122-9.
5. Stratton C. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003; 9:10-6.
6. Lipsitch M, Levin B. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997; 41:363-73.
7. Liu Y, Cui J, Wang R, Wang X, Drlica K, Zhao X. Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J Antimicrob Chemother 2005; 56:1172-5.
8. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112:275-85.
9. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33 (Suppl 3):S147-56.
10. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: measurement and potential use of the mutant selection window. J Infect Dis 2002; 185:561-5.
11. Baquero F, Negri M. Strategies to minimize the development of antibiotic resistance. J Chemother 1997; 9(Suppl):29-37.
12. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:1756-8.
13. Croisier D, Etienne M, Bergoin E, et al. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother 2004; 48:1699-1707.
14. Croisier D, Etienne M, Piroth L, et al. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of quinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 2004; 54:640-7.
15. Etienne M, Croisier D, Charles P-E, et al. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J Infect Dis 2004; 190:1472-5.
16. Scott D, Kling J, Gest G. Characterization of Staphylococcus aureus isolates from patients with toxic shock syndrome, using polyethylene infection chambers in rabbits. Infect Immun 1983; 39:383-7.
17. Fernandez F, Barrett J, Licata L, Amaratunga D, Frosco M. Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess. Antimicrob Agents Chemother 1999; 43: 667-71.
18. Xuan D, Zhong M, Mattoes H, et al. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Antimicrob Agents Chemother 2001; 45:794-9.
19. Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B, Drlica K. Mutant prevention concentration for garenoxacin (BMS-284756) with ciprofloxacin- susceptible and ciprofloxacin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1023-7.
20. Lu T, Zhao X, Li X, Hansen G, Blondeau J, Drlica K. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin, and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 2003; 52:61-4.
21. Liu P, Muller M, Grant M, Obermann B, Derendorf H. Tissue penetration of cefpodoxime and cefixime in healthy subjects. J Clin Pharmacol 2005; 45:564-9.
22. Lu T, Zhao X, Li X, et al. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45:2703-9.
23. Zhou J, Dong Y, Zhao X, et al. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000; 182:517-25.
24. Mouton J, Dudley M, Cars O, Derendorf H, Drusano G. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-7.
25. Craig WA. Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale C, Murakawa T, Ambrose P, eds. Antimicrobial pharmacodynamics in theory and clinical practice. New York: Marcel Dekker, 2002:1-22.
26. Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J Lab Clin Med 2004; 143:269-83.
27. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63:2769-802.
28. Firsov A, Vostrov S, Lubenko I, Drlica K, Portnoy Y, Zinner S. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis: four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1604-13.
29. Zinner S, Lubenko I, Gilbert D, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentration in and out of the mutant selection window: related changes in susceptibility, resistance frequency, and bacterial killing. J Antimicrob Chemother 2003; 52:616-22.
30. Campion J, McNamara P, Evans ME. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother 2004; 48:4733-44.
31. Preston S, Drusano G, Berman A, et al. Pharmacodyamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279:125-9.
32. Olofsson S, Marcusson L, Komp-Lindgren P, Hughes D, Cars O. Selection of ciprofloxacin resistance in Escherichia in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 2006; 57:1116-21.
33. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995; 28:143-60.
34. Sindelar G, Zhao X, Liew A, et al. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 2000; 44:3337-43.
35. Marcusson L, Olofsson S, Lindgren P, Cars O, Hughes D. Mutant prevention concentration of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 2005; 55:938-43.
36. Drlica K, Zhao X, Blondeau J, Hesje C. Low correlation between minimal inhibitory concentration (MIC) and mutant prevention concentration (MPC). Antimicrob Agents Chemother 2006; 50:403-4.